CCO Oncology Podcast
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
- Update frequency
- every 9 days
- Average duration
- 23 minutes
- Episodes
- 208
- Years Active
- 2020 - 2025
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From France
In this episode, Alain Ravaud, MD, PhD, and Marine Gross-Goupil, MD, PhD, discuss in French the latest immuno-oncology developments in the treatment of urothelial cancer.
Presenters:
Alain Ravaud, MD,…
Molecular Classification of Endometrial Carcinoma in the Clinic Today
In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of molecular testing and classification to guide the use of immunotherapy for …
Advances in Immunotherapy for Endometrial Cancer
In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of immunotherapy for the treatment of patients with endometrial cancer. Present… |
Developments in Acute Leukemias: Expert Answers to Clinician Questions
In this episode, David Marks, MD, PhD, and Stéphane de Botton, MD, answer questions from clinicians on management pearls for patients with acute leukemias. Topics include:
- MRD in the management of ALL
- …
Biomarkers in Ovarian Cancer: Expert Discussion of Options for First-line Maintenance Therapy
In this episode, Isabelle Ray Coquard, MD, PhD and Bradley J. Monk, MD, FACS, FACOG, discuss current first-line maintenance therapy options for patients with advanced ovarian cancer.
Presenters:
Prof …
Biomarkers in Ovarian Cancer: Expert Discussion of BRCA Testing and Beyond
Listen to Prof Nicoletta Colombo and Bradley J. Monk, MD, FACS, FACOG, discuss current best practices for biomarker testing for your patients with advanced ovarian cancer.
In this episode, Prof Nicole…
Experts Discuss Evolving State-of-the-Art Management of Patients With HER2-Positive MBC
In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positi…
The Art of Medicine: Clinical Considerations for Patients With Advanced RCC
In this episode, an expert medical oncology panel led by Elizabeth R. Plimack, MD, MS, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses clinical pearls for the management of patients wit…
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 1
In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer questions focused on the optimizing BTK inhibitor therapy for previously untreated patients with CLL cons…
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 3
In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with C…
Clinical Considerations for RET Fusion–Positive NSCLC
In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with …
Chronic Lymphocytic Leukemia: New Horizons With BTK Inhibitors: FAQ Part 2
In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with C…
CAR T Cell Therapy for Lymphoma, Leukemia, and Myeloma: Experts Answer Clinician Questions
In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with …
Practical Application of Immuno-Oncology in RCC: Expert Discussion of Second-line Therapy and Beyond
In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment …
FAQ on New Therapeutic Developments in Relapsed/Refractory Multiple Myeloma
In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed,…
New Advances in Relapsed/Refractory Multiple Myeloma: Frequently Asked Questions on Current and Emerging Treatments
In this episode, Natalie S. Callander, MD, and Shaji Kumar, MD, answer audience questions from a live CCO Webinar on relapsed/refractory myeloma regarding challenges in treating patients in this sett…
Practical Application of Immuno-Oncology in RCC: Expert Discussion of Frontline Therapy
In this episode, Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for the first-line treatment of patients with metastatic renal cell carcin… |
Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma
In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presente… |
MET Exon 14 Mutation–Positive NSCLC: FAQ Part 1
In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on MET exon 14 testing and selecting MET-targeted therapies for patients with advanc…
MET Exon 14 Mutation–Positive NSCLC: FAQ Part 2
In this episode, Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, address questions on biomarking testing and the use of immunotherapy in METex14 mutation–positive NSCL…